Importantly, CSF1R inhibitors are already an approved class of drug for the treatment of Tenosynovial giant cell tumor, and recent work has established the viability of a CSF1R inhibition-based treatment paradigm for Sandhoff disease, further emphasizing the translatability of this strategy178,179. This evidence concerns the gene CSF1R and Sandhoff disease.